News

Breast Implant–Associated lymphoma: Further analysis still needed

Posted Date: February 28, 2013

Greater analysis and prospective evaluation and follow-up of anaplastic large cell lymphoma (ALCL) patients are necessary to definitively resolve the issue of the natural course of the disease and best therapeutic approaches for patients who develop breast implant associated lymphoma.

Implant-associated ALCL (iALCL) may have a better prognosis than more aggressive types of anaplastic large cell lymphoma, however, furrther studies are needed to better understand this disease. A recent study published in The Oncologist, the official journal of the society for translational oncology has identified 44 unique cases of ALCL in association with breast implants. The majority of these patients received multi-agent chemotherapy with or without radiation. The authors suggest further analysis and prospective evaluation and follow-up of iALCL patients are necessary to definitively resolve the issue of the natural course of the disease and best therapeutic approaches for patients who develop breast implant associated lymphoma.